Septerna (NASDAQ:SEPN) Releases Quarterly Earnings Results

Septerna (NASDAQ:SEPN) announced its quarterly earnings results on Monday. The company reported ($0.24) earnings per share for the quarter, FiscalAI reports. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%.

Septerna Price Performance

Shares of NASDAQ SEPN traded up $0.28 during mid-day trading on Monday, hitting $29.06. The company had a trading volume of 556,415 shares, compared to its average volume of 311,979. The company has a market capitalization of $1.30 billion, a PE ratio of -19.25 and a beta of 3.46. The business’s 50-day simple moving average is $26.88 and its 200 day simple moving average is $23.02. Septerna has a 1-year low of $4.66 and a 1-year high of $32.63.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. HC Wainwright increased their price target on shares of Septerna from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. JonesTrading assumed coverage on Septerna in a report on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 price objective on the stock. Wall Street Zen cut Septerna from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 10th. Truist Financial started coverage on Septerna in a research report on Monday, December 15th. They issued a “buy” rating and a $34.00 target price on the stock. Finally, Zacks Research raised Septerna from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Septerna has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Insider Buying and Selling at Septerna

In other news, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total value of $115,880.00. Following the sale, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $5,046,834.73. This trade represents a 2.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Samira Shaikhly sold 70,453 shares of Septerna stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $28.10, for a total transaction of $1,979,729.30. Following the sale, the insider directly owned 793 shares of the company’s stock, valued at approximately $22,283.30. This trade represents a 98.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Septerna

Large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. lifted its holdings in Septerna by 86.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock worth $75,698,000 after buying an additional 1,260,409 shares during the last quarter. First Light Asset Management LLC purchased a new position in shares of Septerna in the 4th quarter valued at about $17,308,000. Primecap Management Co. CA acquired a new stake in shares of Septerna during the 4th quarter worth about $15,225,000. Perceptive Advisors LLC purchased a new stake in Septerna during the second quarter worth approximately $5,723,000. Finally, VR Adviser LLC acquired a new position in Septerna in the second quarter valued at approximately $5,713,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.